New drug duo aims to reboot immune attack on Hard-to-Treat cancers

NCT ID NCT04457778

Completed Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called M6223, which blocks a protein called TIGIT that can turn off immune cells. M6223 was given alone or together with another drug, bintrafusp alfa, to 58 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the combination could help control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M6223 (a drug that blocks TIGIT, a protein on immune cells) and bintrafusp alfa (a drug that targets PD-L1 and TGF-beta)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 58 participants, so it is primarily checking safety and dosing. The drugs may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED SOLID UNRESECTABLE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMORS

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States
Next Oncology

San Antonio, Texas, 78229, United States
Princess Margaret Cancer Centre

Toronto, Canada
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.